Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results from the German Hepatitis C Cohort (GECCO-01)

Clinical Infectious Diseases

Volumn 63, Issue 10, 2016, Pages 1320-1324

  Ingiliz, Patrick ^a   Christensen, Stefan ^b   Kimhofer, Torben ^k   Hueppe, Dietrich ^c   Lutz, Thomas ^d   Schewe, Knud ^e   Busch, Heiner ^b   Schmutz, Günther ^g   Wehmeyer, Malte H ^f   Boesecke, Christoph ^h,i   Simon, Karl Georg ^j   Berger, Florian ^g   Rockstroh, Jürgen K ^h   Zur Wiesch, Julian Schulze ^f   Baumgarten, Axel ^a   Mauss, Stefan ^g  

^a Center for Infectiology (CIB)   (Germany)

^b Center for Interdisciplinary Medicine Muenster   (France)

^c Gastroenterology Practice   (Germany)

^d Infektiologikum   (Germany)

^e Infectiology Center in Hamburg   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g Center for HIV and Hepatogastroenterology   (Germany)

^h UNIVERSITY HOSPITAL BONN   (Germany)

ⁱ Klinische Arbeitsgemeinschaft AIDS   (Germany)

^j Gastroenterology Practice   (Germany)

^k IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

8 weeks; HIV coinfection; ledipasvir; short course treatment; sofosbuvir

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; CHRONIC HEPATITIS C; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GERMANY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NAUSEA; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; VIRUS LOAD; CLINICAL TRIAL; COINFECTION; COMPLICATION; HEPATITIS C, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BENZIMIDAZOLES; COINFECTION; FEMALE; FLUORENES; GERMANY; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SOFOSBUVIR; VIRAL LOAD; YOUNG ADULT;

EID: 84994472462     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw567     Document Type: Article

References (26)

1. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368:1907-17.
2. Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, Van 't Klooster G, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010; 138: 913-21.
3. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother 2015; 59:979-87.
4. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368:34-44.
5. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96-100.
6. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436:933-8.
7. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015; 62(1 suppl):S87-99.
8. Wehmeyer MH, Eissing F, Jordan S, Roder C, Hennigs A, Degen O, et al. Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection. BMC Gastroenterol 2014; 14:87.
9. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 2016; 64:486-504.
10. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:714-25.
11. Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother 2015; 59:5445-54.
12. Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8 weeks vs 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385:1087-97.
13. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-88.
14. O'Brien TR, Feld JJ, Kottilil S, Pfeiffer RM. No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA 6,000,000 IU/mL. Hepatology 2016; 63:28-30.
15. O'Brien TR, Lang Kuhs KA, Pfeiffer RM. Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. Open Forum Infect Dis 2014; 1:ofu110.
16. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63:199-236.
17. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org/full-report/initial-treatment-hcvinfection. Accessed 23 July 2016.
18. Cloherty G, Cohen D, Sarrazin C, Wedemeyer H, Chevaliez S, Herman C, et al. HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals. Antiviral Therapy 2015; 20:177-83.
19. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
20. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-93.
21. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370:222-32.
22. Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med 2015; 163:818-26.
23. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a nonrandomised, open-label trial. Lancet HIV 2015; 2:e319-27.
24. Naggie S, Cooper C, Saag M,Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:705-13.
25. El-Sherif O, Khoo S, Solas C. Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection. Curr Opin HIV AIDS 2015; 10:348-54.
26. Wilder JM, Jeffers LJ, Ravendhran N, Shiffman ML, Poulos J, Sulkowski MS, et al. Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of phase 3 data. Hepatology 2016; 63:437-44.